# A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

> **NCT00044057** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc**

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** YM872 (zonampanel), t-PA (alteplase)

## Key facts

- **NCT ID:** NCT00044057
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** 2003-01
- **Target enrollment:** — (—)
- **Last updated:** 2006-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044057, "A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00044057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*